Login to Your Account



Financings Roundup


Tuesday, January 24, 2012
• EntreMed Inc., of Rockville, Md., raised $10 million through the issuance of convertible notes and warrants to certain accredited investors. The company issued $10 million worth of notes as well as warrants equal to 20 percent of the principal amount of the notes, divided by $1.15. Proceeds of $9.3 million will help EntreMed advance its Aurora A/angiogenic kinase inhibitor ENMD-2076, which is in Phase II for ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription